EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigation of Aberrant Basaloid Cells in a Rat Model of Lung Fibrosis

Emanuela Bocchi, Vanessa Pitozzi, Silvia Pontis, Paola L Caruso, Sofia Beghi, Mariafrancesca Caputi, Marcello Trevisani, Francesca Ruscitti

Frontiers in Bioscience-Landmark · 22.08.2024 · 29 (8)

DOI: 10.31083/j.fbl2908305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 22.08.2024. Verfasst von Emanuela Bocchi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Psychology, Drug Area and Child Health, University of Florence, 50139 Florence, Italy. Hauptthemen laut MEDLINE: Disease Models, Animal, Bleomycin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chiesi Farmaceutici S.p.A.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease (ILD) whose cause and pathogenesis are not yet well understood. Until now, no animal model of lung fibrosis succeeds in recapitulating all IPF features, thus the use of different rodent models is essential for the evaluation and development of new effective pharmacological treatments. Recently, the alveolar epithelial dysfunction has been emphasized in the etiopathogenesis context of IPF. Remarkably, the role of an aberrant basaloid cell type, primarily found in humans and confirmed in mice, seems to be crucial in the establishment and progression of the disease/model. Our work aimed to characterize for the first time this cell population in a rat model of lung fibrosis induced by a double bleomycin (BLM) administration, demonstrating the translational value of the model and its potential use in the testing of effective new drugs.

Methods

Rats received an intratracheal BLM administration at day 0 and 4. Animals were sacrificed 21 and 28 days post-BLM. The fibrosis evaluation was carried out through histological (Ashcroft score and automatic image analysis) and immunoenzymatic analysis. Immunofluorescence was used for the characterization of the aberrant basaloid cells markers.

Results

Lung histology revealed an increase in severe grades of Ashcroft scores and areas of fibrosis, resulting in a rise of collagen deposition at both the analyzed time-points. Immunofluorescence staining indicated the presence of KRT8+ cells in bronchial epithelial cells from both controls (saline, SAL) and BLM-treated animals. Interesting, KRT8+ cells were found exclusively in the fibrotic parenchyma (confirmed by the alpha-smooth muscle actin (α-SMA) staining for myofibroblasts) of BLM-treated animals. Moreover, KRT8+ cells co-expressed markers as Prosurfactant protein C (Pro-SPC) and Vimentin, suggesting their intermediate state potentially originating from alveolar type II (AT2) cells, and participating to the abnormal epithelial–mesenchymal crosstalk.

Conclusion

Previous preclinical studies demonstrated the presence of KRT8+ aberrant basaloid-like cells in murine models of lung fibrosis. This work investigated the same cell population in a different rodent (the rat) model of lung fibrosis triggered by a double administration of BLM. Our results provided a further confirmation that, in rats, the intratracheal administration of BLM induced the appearance of a population of cells compatible with the KRT8+ alveolar differentiation intermediate (ADI) cells, as described previously in the mouse. This piece of work enforces previous evidence and further support the use of a rat model of BLM resembling the alveolar epithelial dysfunction to evaluate new clinical candidates for development in IPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disease Models, AnimalBleomycinAnimalsRatsMalePulmonary FibrosisLungIdiopathic Pulmonary Fibrosis

Stichwörter der Autor:innen

IPFKRT8+ epithelial cellsaberrant basaloid cellsbleomycinbronchiolizationfibroblastic fociidiopathic pulmonary fibrosisprogressive pulmonary fibrosis

Substanzen

Bleomycin

Autor:innen und Institutionen

  • Department of Neuroscience, Psychology, Drug Area and Child Health, University of Florence, 50139 Florence, Italy.
  • Target Innovation Department, Global Research and Preclinical Development, Chiesi Farmaceutici S.p.A., 43122 Parma, Italy.
  • Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.

Förderung

  • Chiesi Farmaceutici S.p.A

Zitieren

APA

Bocchi, E., Pitozzi, V., Pontis, S., Caruso, P. L., Beghi, S., Caputi, M., Trevisani, M., & Ruscitti, F. (2024). Investigation of Aberrant Basaloid Cells in a Rat Model of Lung Fibrosis. Frontiers in Bioscience-Landmark, 29(8). https://doi.org/10.31083/j.fbl2908305

Vancouver

Bocchi E, Pitozzi V, Pontis S, Caruso PL, Beghi S, Caputi M, et al. Investigation of Aberrant Basaloid Cells in a Rat Model of Lung Fibrosis. Frontiers in Bioscience-Landmark. 2024;29(8). doi:10.31083/j.fbl2908305

BibTeX
@article{Bocchi2024,
  author = {Bocchi, Emanuela and Pitozzi, Vanessa and Pontis, Silvia and Caruso, Paola L and Beghi, Sofia and Caputi, Mariafrancesca and Trevisani, Marcello and Ruscitti, Francesca},
  title = {Investigation of Aberrant Basaloid Cells in a Rat Model of Lung Fibrosis},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2024},
  volume = {29},
  number = {8},
  doi = {10.31083/j.fbl2908305}
}
Kostenlos starten →